A086820 Stock Overview
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Bio Solution Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩17,860.00 |
| 52 Week High | ₩24,050.00 |
| 52 Week Low | ₩9,210.00 |
| Beta | 0 |
| 1 Month Change | 5.87% |
| 3 Month Change | 7.66% |
| 1 Year Change | 36.34% |
| 3 Year Change | -35.64% |
| 5 Year Change | -59.41% |
| Change since IPO | -37.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| A086820 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -6.6% | -0.2% | 1.0% |
| 1Y | 36.3% | 7.7% | 8.7% |
Return vs Industry: A086820 exceeded the KR Biotechs industry which returned 7.7% over the past year.
Return vs Market: A086820 exceeded the KR Market which returned 8.7% over the past year.
Price Volatility
| A086820 volatility | |
|---|---|
| A086820 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A086820 has not had significant price volatility in the past 3 months.
Volatility Over Time: A086820's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | n/a | www.biosolutions.co.kr |
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2nd-degree burn wounds; and KeraHeal, an autologous spray-type keratinocyte cell-based therapy for skin wounds.
Bio Solution Co.,Ltd. Fundamentals Summary
| A086820 fundamental statistics | |
|---|---|
| Market cap | ₩143.30b |
| Earnings (TTM) | -₩1.28b |
| Revenue (TTM) | ₩8.27b |
0.0x
P/S Ratio0.0x
P/E RatioIs A086820 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086820 income statement (TTM) | |
|---|---|
| Revenue | ₩8.27b |
| Cost of Revenue | ₩3.57b |
| Gross Profit | ₩4.70b |
| Other Expenses | ₩5.98b |
| Earnings | -₩1.28b |
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A086820 perform over the long term?
See historical performance and comparison